The mechanism of action of calcium channel blockers in the treatment of diabetic nephropathy

International Journal of Diabetes and Metabolism

Volumn 13, Issue 2, 2005, Pages 76-82

  Yousef, Wael Mohamed ^a   Omar, Adel H ^a   Morsy, Mohamed D ^a   Abd El Wahed, Moshira M ^a   Ghanayem, Naglaa M ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Amlodipine; Calcium channel blockers; Diabetes mellitus; Diabetic nephropathy; Diltiazem; Ischaemia

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 4 (2,1,3 BENZOOXADIAZOL 4 YL) 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; AMLODIPINE; ATENOLOL; BENIDIPINE; BEPRIDIL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM CHANNEL T TYPE; CAPTOPRIL; CINNARIZINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUNARIZINE; INDOMETACIN; LISINOPRIL; LOSARTAN; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PHENYTOIN; PLACEBO; PRENYLAMINE; PROPRANOLOL; SDZ 20279; TIAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL;

BINDING AFFINITY; CALCIUM CURRENT; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; HEALTH CARE COST; HEART ATRIOVENTRICULAR NODE; HEART INFARCTION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MEMBRANE PERMEABILITY; MONOTHERAPY; NONHUMAN; PROTEINURIA; REVIEW; RISK ASSESSMENT; SINUS NODE; SODIUM CURRENT; TREATMENT OUTCOME; UNITED STATES; VASODILATATION;

EID: 29744447082     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: 10.1159/000497574     Document Type: Review

References (40)

1. Greer JW, Milam RA, Eggers PW. Trends in use, cost and outcomes of human recombinant erythropoietin. Health Care Finance Rev 1999; 20: 55-62.
2. Macdougall IC, Chandler G, Elston O. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999; 34: S40-S46.
3. Berridge MJ. Inositol Triphosphate and Calcium Signaling. Nature 1993; 361:315-325.
4. Tsien RW, Lipscombe D, Madison DV, Bley KR, Fax AP. Multiple types of neuronal calcium channels and their selective modulation. Trends Neurosci 1988; 11:431-438.
5. Bevan JA, Bevan RD, Huo JJ, Qwen MP, Tayo FM, Winquist RJ. Calcium extrinsic and intrinsic vascular tone in international symposium on calcium modulators. Elsevier Biomedical Press, 1982; P125-32.
6. Schwartz A. Molecular and cellular aspects of calcium antagonism. Am J Cardiol 1992;70:6F-8F.
7. Morad M, Nayler W, Kazda S. The calcium channel: structure, function and implications, New York; Springer-Verlag,1988.
8. Singer D, Biel M, Lotan I, et al. The roles of the subunits in the function of the calcium channel. Science 1991; 253: 1553-1556.
9. Spedding M, Paoletti R. Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 1992;44:363-376.
10. Rybak ME, Renzulli LA. Effect of calcium channel blockers on platelet GPIIb-iiia as a calcium channel in liposomes: comparison with effects on the intact platelet. Thromb. Haemostas 1992; 67:131-136.
11. Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 1985; 316:440-443.
12. Llinas RP, Sugimori M, Cherksey B. Voltage-dependent calcium conductances in mammalian neurons: the P channel. Ann N Y Acad Sci 1989; 560:103-111.
13. Katz AM, Hager WD, Messineo FC. Calcium Channel Blockers. Am J Med 1985;77 (Suppl2B):2-10.
14. Vanhoutte PM, Paoletti R, Govoni S. Calcium antagonists: pharmacology and clinical research. Ann NY Acad Sci 1988; 522:169-182.
15. Fleckenstein A. Calcium Channel Blockers. Exper Facts and Therap Prospect, 1983.
16. Robertson RM, Robertson D. Drugs used for the treatment of Myocardial Ischaemia In: Hardman, J.G. and Limbird L.E. (eds.) Goodman and Gillman's. The pharmacological Basis of Therapeutics, McGrawv-Hill, USA 1996; P767-P779.
17. Janis RA, Silver PJ, Triggle DG. Drug action and cellular calcium regulation. Adv Drug Res 1987; 16:309
18. Rang HP, Dale MM, Ritter JM. Drugs that affect cardiac function. Churchill Livingstone, 1999; P261-P77.
19. Vaghy PL, Williams JS, Schwartz, A. Receptor pharmacology of calcium entry blocking agents. Am J Cardiol 1987; 59: 9A.
20. Bretzel RG. Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy. J Diabetes Complications 1997; 11: 112-122.
21. Tarif N, Bakris G. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 13: 2244-2250.
22. Luno J, Garcia de Vinuesa S, Gomez-Campdera F, Lorenzo I. Hypertension and renal diseases. Kidney Int Suppl 1998; 68: S112-9.
23. Parving HH, Tarnow L, Rossing P. Renal protection in diabetes an emerging role foe calcium antagonists. Cardiology 1997; 88 (Suppl) 3: 56-62.
24. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889-896.
25. Deray G. Nephroprotective effect of calcium antagonists. Press Med 1999; 28: 1667-1670.
26. U.K. Prospective Diabetes Study Group (UKPDS). Intensive blood glucose control with insulin compared to conventional treatment and risk complications in patients with type II diabetes. Lancet 1998; 352: 837.
27. Estacio RO, Jeffers BW, Hiatt WR. The effect of nisoldipine and enalapril in treatment of diabetic hypertensive patients. N Eng J Med 1998; 338: 645.
28. Gerstein HC. Preventive medicine in a diabetic clinic. Lancet 1999; 353: 606.
29. Nielsen B, Gronbaek H, Osterby R, Orskov H, Flyvbjerg A. The calcium channel blocker nitrendipine attenuates renal glomerular hypertrophy in diabetic rats. Exp Nephrol 1999; 7:242-250.
30. Suzuki H, Saruta T. Effects of calcium antagonists, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clin Exp Hypertens 2001; 23: 189-201.
31. Shigihara T, Sato A, Hayashi K, Saruta T. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin execretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res 2000; 23: 219-226.
32. Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 2000; 12: 80S-85S.
33. The Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
34. Vittorio EA, Maurizio G, Diego B. ACE-inhibitors and progression of chronic renal insufficiency. J Nephrol 1998; 11:P105-109.
35. Wilmer WA, Hebert LA, Lewis EJ. Remission of nephritic syndrome in type I diabetes: long term follow-up of patients in the captopril study. Am J Kidney Dis 1999; 34: 308.
36. Chan JC, Ko GT, Leung DH. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type II diabetic patients. Kidney Int 2000; 570: 590.
37. Lewis JB, Berl T, Bain RP. Effect of intensive blood pressure control on the course of type I diabetic nephropathy. Am J Kidney Dis 1999; 34: 809.
38. Hansen HP, Rossing P, Tarnow L. Increased glomerular filtration rate after withdrawal of long- term antihypertensive treatment in diabetic nephropathy. Kidney Int 1998; 47:1726.
39. De-Courten M, Boehlen LM, Weidmann P. Comparative study of the effect of ACE-I and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens, 1994; 7(pt2): 84S.
40. Vivan EM, Geobig ML. Slowing the progression of renal disease in diabetic patients. Ann Pharmacother 2001; 35:452-463.